PBM Act
- Sponsor
- Sen. Warren, Elizabeth [D-MA]
- Committees
- Judiciary Committee (primary)
- Last action
- May 13, 2026
Bottom line
The Patients Before Monopolies Act aims to structurally separate pharmacy benefit managers and insurance companies from pharmacies to eliminate conflicts of interest, foster competition, and potentially lower prescription drug costs for consumers.
What it actually does
This bill prohibits any person from directly or indirectly owning, operating, or controlling both a pharmacy and an insurance company or pharmacy benefit manager (PBM). It mandates that any entity currently in violation of this prohibition must divest its pharmacy assets within one year of the Act's enactment. The bill grants enforcement authority to the Federal Trade Commission (FTC) and the Department of Justice (DOJ), establishes penalties for non-compliance, and creates both federal and private rights of action to enforce the structural separation.
Proponents argue
Supporters argue that this bill is essential to address the highly concentrated and vertically integrated market for pharmacy benefit manager services, which they contend leads to anticompetitive practices, increased prescription drug costs for patients, and reduced competition for independent pharmacies. They assert that structural separation will eliminate conflicts of interest, prevent large health conglomerates from self-preferencing their affiliated pharmacies, and stop the alleged evasion of Medical Loss Ratio limits through transfer pricing, ultimately benefiting patients, independent pharmacies, and taxpayers.
Opponents contend
Critics of similar proposals typically argue that vertical integration creates efficiencies, lowers administrative costs, and allows for better coordinated care, ultimately benefiting patients through integrated services and potentially lower prices. They might contend that forced divestiture would disrupt existing healthcare models, lead to increased administrative burdens, and could result in higher costs for consumers due to the loss of these efficiencies. Opponents may also raise concerns about the government's intervention in private markets and the potential for unintended negative consequences on patient access or choice.
The bill is relatively short and clearly written for its scope, making it accessible for an informed reader to evaluate its core provisions within a reasonable timeframe.
Section 3(a)
Prohibition on Common Ownership of PBMs/Insurers and Pharmacies
This provision makes it illegal for any individual or entity to simultaneously own or control a pharmacy and an insurance company or a pharmacy benefit manager (PBM). It mandates that any person currently engaged in such common ownership must divest their pharmacy assets within one year of the bill becoming law. This aims to structurally separate these entities to prevent conflicts of interest.
Supporters argue
Supporters argue that this provision directly addresses the core conflict of interest where PBMs and insurers can self-preference their own pharmacies, leading to inflated drug costs and unfair competition. By forcing structural separation, it aims to restore a competitive marketplace, protect independent pharmacies, and ultimately lower costs for consumers and health plans.
Critics contend
Opponents might contend that this forced divestiture is an extreme measure that disregards the potential efficiencies and integrated care benefits that vertical integration can offer. They may argue that it could disrupt patient access to care, increase administrative costs, and lead to unintended consequences for the healthcare supply chain, without guaranteeing lower drug prices.
Tradeoffs
The provision balances the goal of eliminating conflicts of interest and fostering competition against the potential disruption to existing integrated business models and the loss of any efficiencies derived from such integration. It also weighs the benefits of market restructuring against the significant costs and complexities of forced divestiture.
Section 3(b)
Antitrust Enforcement and Divestment Penalties
This section grants both the Federal Trade Commission (FTC) and the Assistant Attorney General of the Antitrust Division of the Department of Justice (DOJ) joint or separate jurisdiction to enforce the common ownership prohibition. It requires guidance on divestment milestones within 30 days and imposes significant penalties for non-compliance: 10% of a person's profits will be transferred into escrow monthly, to be returned upon divestment or deposited into a fund if divestment does not occur by the deadline. If divestiture fails, a trustee will be appointed to oversee the sale of the pharmacy.
Section 3(c)
Public and Private Rights of Action
This section establishes multiple avenues for legal action against violations of the common ownership prohibition. It allows the Inspector General of the Department of Health and Human Services, the DOJ Antitrust Division, the FTC, and State Attorneys General to bring civil actions. Crucially, it also creates a private right of action, enabling individuals who allege damages from a violation to sue for treble damages, attorney's fees, and other relief. Courts are mandated to issue orders requiring cessation of violations, divestment, and disgorgement of revenue from prescription drug sales into a fund for harmed communities. A right to a jury trial is also guaranteed.
Section 3(d)
Enhanced Antitrust Review of Divestitures and Future Transactions
This provision requires that any divestment of a pharmacy or PBM mandated by the Act must be reported to the FTC and DOJ under Section 7A of the Clayton Act, regardless of standard financial thresholds. The divestment period is tolled (paused) during this review. The FTC and DOJ are further mandated to review the effect of each divestiture and subsequent acquisition on competition, financial viability, and the public interest. They are also granted explicit authority to block any future actions that would harm competition by re-creating the conflicts of interest addressed in the bill.
Section 3(i)
Broad Definitions of 'Pharmacy' and 'Pharmacy Benefit Manager'
This section provides expansive definitions for 'pharmacy' and 'pharmacy benefit manager' (PBM) to ensure comprehensive coverage under the Act. 'Pharmacy' includes virtually all types of pharmacies, such as mail-order, specialty, retail, nursing home, long-term care, hospital, and infusion pharmacies, explicitly including any organization with relevant National Provider Identifier (NPI) taxonomy codes. 'Pharmacy benefit manager' is defined broadly to include any entity that negotiates prices/rebates, contracts with pharmacies for networks, or manages/administers prescription drug benefits, regardless of how they identify themselves, and explicitly includes affiliates, subsidiaries, or agents.
For non-compliance with divestment milestones, 10% of a person's monthly profits are transferred into escrow. If divestment doesn't occur by the deadline, these escrowed funds, along with any revenue disgorged from civil actions, are deposited into a fund created by the Federal Trade Commission. This fund is to be distributed by the FTC to serve the healthcare needs of the harmed community, including consumers overcharged at vertically integrated pharmacies.
Section 3(b)(2)(B)(i) and (c)(7)
Why it matters:This is a standard legislative practice to define a fund's purpose and distribution mechanism in a dedicated subsection, rather than repeating it in every instance of a penalty or disgorgement. However, its placement means a casual reader might miss the specific mechanism for consumer redress.
Case for: Supporters would argue that this mechanism provides a direct form of restitution to communities and consumers harmed by anticompetitive practices. It ensures that financial penalties and ill-gotten gains are not simply absorbed by the government but are redirected to address the very issues the bill seeks to remedy, enhancing the bill's consumer protection aspect.
Case against: Critics might argue that the creation and administration of such a fund could be complex and costly for the FTC, potentially diverting resources from its core antitrust enforcement functions. They might also question the practicalities of identifying and distributing funds to 'harmed communities' or 'consumers overcharged,' suggesting it could be an inefficient or difficult process to implement fairly.
Estimated impact: Potentially billions of dollars in penalties and disgorged profits could be directed to this fund, depending on the scale of non-compliance and successful civil actions, significantly impacting healthcare services for affected communities.
Any divestment of a pharmacy or pharmacy benefit manager required under subsection (a) shall be reported to the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice under section 7A of the Clayton Act (15 U.S.C. 18a) without respect to the thresholds under subsection (a)(2) of that section.
Section 3(d)(1)
Why it matters:This is standard legislative drafting for modifying existing law. The reference to the Clayton Act is precise. However, its technical nature means the full implication of universal reporting for these divestitures could be overlooked.
Case for: Supporters would argue that this ensures all mandated divestitures, regardless of their financial size, receive full antitrust scrutiny. This prevents smaller, but potentially strategically significant, divestitures from escaping review, thereby ensuring the comprehensive implementation of the bill's goals and preventing future anticompetitive structures.
Case against: Critics might contend that removing the Clayton Act's thresholds for these specific divestitures could impose an unnecessary administrative burden on both the divesting companies and the antitrust agencies. They might argue that smaller transactions, which would typically not warrant such extensive review, could be unduly delayed or complicated, adding to the overall cost and complexity of the divestment process.
Estimated impact: This provision ensures that potentially dozens of divestitures, including those below typical reporting thresholds, will undergo rigorous federal antitrust review, increasing the oversight burden on agencies and the compliance burden on companies.